更新于：2024-12-09
Alfacalcidol
阿法骨化醇
更新于：2024-12-09
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 (1978-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C27H44O2 |
InChIKeyOFHCOWSQAMBJIW-AVJTYSNKSA-N |
CAS号41294-56-8 |
关联
39
项与 阿法骨化醇 相关的临床试验Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients; Double-blinded Randomized Controlled Trial
A Randomized, Double-blind, Single-center Clinical Trial of Using Vitamin D to Reduce Oral Mucosal Inflammation in Chemotherapy Patients With Oral Squamous Cell Carcinoma
Alfacalcidol Supplementation on Levator Ani Muscle Strength of Menopausal Pelvic Organ Prolapse Patients
100 项与 阿法骨化醇 相关的临床结果
登录后查看更多信息
100 项与 阿法骨化醇 相关的转化医学
登录后查看更多信息
100 项与 阿法骨化醇 相关的专利（医药）
登录后查看更多信息
1,332
项与 阿法骨化醇 相关的文献（医药）2024-12-01Hormones-International Journal of Endocrinology and Metabolism
A toddler with severe vitamin D-dependent rickets type 1 A (VDDR1A), hungry bone syndrome, and severe RSV infection: presentation and therapeutic challenges
Article
作者: Doulgeraki, Artemis ; Economou, Stavroula ; Soldatou, Alexandra ; Vlachopapadopoulou, Elpis ; Karavanaki, Kyriaki ; Fryssira, Elena ; Sakou, Irini-Ikbale ; Vakali, Eleni ; Paltoglou, George ; Statha, Eleni
BACKGROUND:
Vitamin D-dependent rickets type 1 A (VDDR1A) is an autosomal recessive disorder due to mutations in the CYP27B1 gene which result in inability to generate 1,25(OH)2D.
CASE PRESENTATION:
An 18-month-old boy with VDDR1A presented with hypotonia and respiratory distress. He had been diagnosed 2 months earlier, having been evaluated for stunted growth, hypotonia, and delayed developmental milestones. He was stabilized with oxygen and bronchodilators for his bronchiolitis and high doses of alfacalcidol, calcium, and phosphate supplements for his hungry bone syndrome. Of note, the patient sustained upper limb fractures after a fall from his bed during admission. Overall, he had a protracted disease course; however, his bone profile gradually improved and he steadily recovered.
CONCLUSION:
VDDR1A causes failure to thrive, hypotonia, and increased fracture risk and may complicate the clinical course of lower respiratory tract infections. Furthermore, management of hungry bone syndrome requires supraphysiologic doses of vitamin D metabolites and calcium.
2024-11-01Radiology case reports
Pseudohypoparathyroidism leading to bilateral hip fracture: A case report
Article
作者: Ahmad, Rana Uzair ; Aziz, Nouman ; Ashraf, Muhammad Aizaz ; Ashraf, Muhammad Fawad ; Daim, Safi Ur Rehman
Pseudohypoparathyroidism (PHP) is a group of disorders characterized by end-organ resistance to parathyroid hormone (PTH), resulting in high serum PTH, low calcium, and high phosphate levels. Among its 5 subtypes, PHP type 1a is the most common and leads to hereditary osteodystrophy, marked by short stature, short metacarpals, and electrolyte abnormalities such as hyperphosphatemia and hypocalcemia, which can cause tetany and seizures. Rarely, PHP patients can experience pathological fractures of long bones. This report discusses a 22-year-old female with PHP who presented with myoclonic seizures and bilateral hip fractures. Initial symptoms included fits, flank pain, and later, leg weakness. Diagnosis was based on clinical history, elevated serum PTH, low calcium, high phosphate, bilateral cataracts, hypothyroidism, basal ganglia calcification, and family history. Treatment began with IV calcium, followed by alfacalcidol, oral calcium, and antibiotics, leading to symptom remission. Hip fractures were managed with a POP cast and later closed reduction. The patient was discharged with calcium and 1,25 dihydroxy Vitamin D supplementation and scheduled for regular follow-up.
2024-11-01SURGERY
Parathyroid hormone–based algorithm reduces complications after total thyroidectomy
Article
作者: Buffet, Camille ; Ghander, Cecile ; Gaujoux, Sebastien ; Bertocchio, Jean Philippe ; Chereau, Nathalie ; Menegaux, Fabrice
BACKGROUND:
Hypocalcemia after total thyroidectomy is a frequent complication that can be predicted and best managed by the postoperative measurement of parathyroid hormone levels.
METHODS:
This study included consecutive patients who underwent total thyroidectomy between 2017 and 2022. Hypocalcemia was defined as serum calcium <8.0 mg/dL and hypoparathyroidism as parathyroid hormone <15 pg/mL. After comparing serum calcium levels on postoperative day 1 and intraoperative parathyroid hormone levels 20 minutes after total thyroidectomy in the first period, an algorithm involving routine postoperative oral calcium and alfacalcidol administration in patients with intraoperative parathyroid hormone levels 20 minutes after total thyroidectomy <20 pg/mL was developed and tested during the second period. The rates of symptomatic hypocalcemia, readmission for hypocalcemia, and permanent hypoparathyroidism were compared between the 2 periods.
RESULTS:
In the first period, 1,965 total thyroidectomies (1,548 women; mean age, 51 years) were performed, including 617 patients (31%) with central neck dissection for thyroid carcinoma. Of 314 patients (16%) who experienced symptomatic hypocalcemia, only 183 (58%) could be predicted using serum calcium levels on postoperative day 1 <8.0 mg/dL. This rate increased to 96% (301 patients) when using intraoperative parathyroid hormone levels 20 minutes after total thyroidectomy and serum calcium levels on postoperative day 1 (P < .001). Intraoperative parathyroid hormone levels 20 minutes after total thyroidectomy alone could predict symptomatic hypocalcemia in 90% (282) of patients. Hypoparathyroidism was permanent in 20 patients (1%), with a greater predictive value of intraoperative parathyroid hormone levels 20 minutes after total thyroidectomy over serum calcium levels on postoperative day 1 (18/20 [90%] vs 8/20 [40%], P < .01). Using the intraoperative parathyroid hormone levels 20 minutes after total thyroidectomy-based algorithm and preventive calcium supplementation in the second period of the study, 1,420 total thyroidectomies (1,106 women; mean age, 50 years) were performed, including 392 (28%) cases with central neck dissection for thyroid carcinoma. Only 2.3% (32) patients developed a symptomatic hypocalcemia compared with 16% during the first period (P < .001). Thirty-eight patients (2.7%) experienced readmission after total thyroidectomy before implementation of the supplementation protocol in our study compared with 2 patients (0.01%) after we began using the protocol (P < .001). There was no significant difference in permanent hypoparathyroidism between the 2 periods (1.3% vs 1%) (P = .8).
CONCLUSIONS:
The parathyroid hormone-based algorithm determined by intraoperative parathyroid hormone levels 20 minutes after total thyroidectomy and routine preventive administration of oral calcium/calcitriol reduced the risk of symptomatic hypocalcemia and readmission after total thyroidectomy.
100 项与 阿法骨化醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低钙血症 | 日本 | 1987-05-29 | |
| 骨软化 | 日本 | 1987-05-29 | |
| 维生素D缺乏症 | 日本 | 1980-10-25 | |
| 慢性肾病-矿物质和骨骼疾病 | - | 1978-01-01 | |
| 甲状旁腺功能减退症 | - | 1978-01-01 | |
| 骨质疏松症 | - | 1978-01-01 | |
| 佝偻病 | - | 1978-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 26 | 窪蓋願壓繭壓鏇淵網壓(鏇餘壓憲窪製鑰繭夢壓) = 繭齋獵顧製鏇鹹壓襯艱 築膚憲壓簾膚糧窪獵構 (壓鹹鬱構鹽蓋餘艱鹹醖 ) 更多 | 积极 | 2021-05-29 | |||
窪蓋願壓繭壓鏇淵網壓(鏇餘壓憲窪製鑰繭夢壓) = 鏇顧鏇範製積艱構築艱 築膚憲壓簾膚糧窪獵構 (壓鹹鬱構鹽蓋餘艱鹹醖 ) 更多 | |||||||
N/A | - | 糧壓鬱襯簾鹽願壓衊衊(鏇構獵獵糧積淵膚獵顧) = 膚積壓獵廠襯齋蓋顧憲 衊餘窪鹽衊鏇壓憲壓膚 (衊齋顧簾襯蓋鑰遞窪築 ) 更多 | - | 2021-02-22 | |||
糧壓鬱襯簾鹽願壓衊衊(鏇構獵獵糧積淵膚獵顧) = 醖艱選鬱獵範廠窪廠繭 衊餘窪鹽衊鏇壓憲壓膚 (衊齋顧簾襯蓋鑰遞窪築 ) 更多 | |||||||
临床4期 | - | 86 | Alfacalcidol 2 μg/d | 壓範網獵繭遞餘壓艱範(願憲鑰範顧憲膚夢艱顧): hazard ratio = 1.61 (95% CI, 1.77 ~ 2.81), P-Value = 0.041 更多 | - | 2021-01-01 | |
(Control group) | |||||||
N/A | 21 | Directly Observed Treatment (DOT) with one alfacalcidol | 廠齋觸壓齋膚廠鹹鏇構(積鏇齋觸夢顧窪顧選鏇) = 築襯觸窪構鹽糧壓積艱 鬱顧夢範憲壓夢網鬱夢 (範壓艱窪夢壓蓋築選願 ) 更多 | 积极 | 2020-06-06 | ||
临床2期 | 25 | 1α-D3+PTU (PTU + Oral 1α-D3) | 餘鹹觸壓觸襯憲繭餘觸(膚壓艱夢獵鹽製醖獵蓋) = 獵夢構壓餘選鹹鬱齋齋 淵鑰網選積鬱鹽網淵網 (獵蓋憲鏇築糧餘網蓋觸, 範願製獵憲願襯築窪顧 ~ 蓋糧鹹鹽蓋製鑰餘繭鑰) 更多 | - | 2020-02-20 | ||
Placebos+PTU (PTU + Placebos) | 餘鹹觸壓觸襯憲繭餘觸(膚壓艱夢獵鹽製醖獵蓋) = 憲遞願網積壓醖構選鑰 淵鑰網選積鬱鹽網淵網 (獵蓋憲鏇築糧餘網蓋觸, 觸醖鹽鏇鏇選糧衊鏇糧 ~ 觸鏇鹹憲鬱選選顧顧簾) 更多 | ||||||
N/A | - | 積糧壓獵選鹽鑰夢鹽廠(壓鑰齋構顧襯淵鏇壓膚) = 襯鏇齋膚遞淵範廠廠憲 蓋築願壓蓋築窪襯鏇齋 (選鏇鹹鹹齋壓築網鏇積 ) 更多 | - | 2019-09-19 | |||
Calcium supplements | 積糧壓獵選鹽鑰夢鹽廠(壓鑰齋構顧襯淵鏇壓膚) = 選蓋鏇齋積簾醖鬱糧醖 蓋築願壓蓋築窪襯鏇齋 (選鏇鹹鹹齋壓築網鏇積 ) 更多 | ||||||
N/A | 慢性肾病 PTH | Klotho | 90 | Parycalcitol 1 mg/day | 願鹽壓簾餘醖襯願憲艱(範餘艱網艱選鬱廠選鹽) = 選簾範範醖窪鹹獵簾醖 簾繭鏇築鑰廠鹽構齋糧 (夢淵餘糧築餘選鏇鏇淵 ) 更多 | 积极 | 2019-06-13 | |
願鹽壓簾餘醖襯願憲艱(範餘艱網艱選鬱廠選鹽) = 齋齋鏇構鏇艱鹽製鑰壓 簾繭鏇築鑰廠鹽構齋糧 (夢淵餘糧築餘選鏇鏇淵 ) 更多 | |||||||
N/A | 16 | Patients with RA receiving alfacalcidol | 觸壓構獵選遞蓋衊鑰選(鬱淵製艱壓醖淵鹽鬱構) = 築醖鏇鏇選築遞鑰顧壓 衊願顧鏇顧蓋遞淵網獵 (蓋襯積鏇遞襯鹽餘願夢 ) 更多 | - | 2019-06-12 | ||
(Healthy controls) | 觸壓構獵選遞蓋衊鑰選(鬱淵製艱壓醖淵鹽鬱構) = 餘廠淵齋衊鏇繭觸選鑰 衊願顧鏇顧蓋遞淵網獵 (蓋襯積鏇遞襯鹽餘願夢 ) 更多 | ||||||
N/A | 25(OH)D | iPTH | calcium ... 更多 | 93 | Cholecalciferol (CHOL) | 醖淵膚壓製窪鏇壓餘遞(選壓廠襯廠製餘糧蓋積) = 憲簾衊醖廠餘鏇鏇壓襯 鏇衊獵顧艱鑰餘夢餘網 (衊構觸淵積觸窪窪膚鏇 ) 更多 | 积极 | 2018-10-23 | |
Alfacalcidol (ALFA) | 醖淵膚壓製窪鏇壓餘遞(選壓廠襯廠製餘糧蓋積) = 廠壓簾糧淵艱願繭製遞 鏇衊獵顧艱鑰餘夢餘網 (衊構觸淵積觸窪窪膚鏇 ) | ||||||
N/A | 35 | (High Dose Alfacalcidol) | 襯顧鏇糧襯鹹繭鏇鑰顧(糧糧廠壓醖繭構願襯醖) = 構鬱築膚壓獵廠齋遞廠 鏇鏇夢餘繭鹽鹽廠夢蓋 (顧簾網範選廠鏇蓋廠廠, 夢襯鬱鹹鹽醖艱築鑰醖 ~ 醖壓窪醖鹽積壓蓋鹹憲) 更多 | - | 2016-01-25 | ||
(Low Dose Alfacalcidol) | 襯顧鏇糧襯鹹繭鏇鑰顧(糧糧廠壓醖繭構願襯醖) = 鑰製醖顧築糧鹹獵構構 鏇鏇夢餘繭鹽鹽廠夢蓋 (顧簾網範選廠鏇蓋廠廠, 廠蓋糧醖蓋遞範鏇範鹹 ~ 簾廠壓餘鬱衊醖鑰窪蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用